Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Blood (2023) 142 (Supplement 1): 4641.

https://doi.org/10.1182/blood-2023-181595

Published: 2023

Journal Articles

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy

Blood (2021) 138 (Supplement 1): 3876.

https://doi.org/10.1182/blood-2021-154225

Published: 2021

Journal Articles

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

Blood (2021) 137 (14): 1970–1979.

https://doi.org/10.1182/blood.2020009050

Published: 2021

Includes: Supplemental data

Journal Articles

A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up

John Moore, MB.BS, MD FRACP, FRCPA, John Kwan, MBBS,FRACP,FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Ashish Bajel, FRACP, David Ritchie, MB ChB, PhD FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Steven Tran, BEng MBiomedE, Donna Aarons, B.Pharm, Nada Hamad, MB.BS, FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-142131

Published: 2020

Journal Articles

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Forat Lutfi, MD, Ankit Kansagra, MD, Moaath Mustafa Ali, MD, Ali Bukhari, MD, Jonathan Siglin, BS, Jingsheng Yan, PhD, Santanu Samanta, MD, Noa G. Holtzman, MD, David Gottlieb, MD, Dong Won Kim, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Jean A. Yared, MD, Nancy M. Hardy, MD, Jason Molitoris, MD, Pranshu Mohindra, MD, Aaron P. Rapoport, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141231

Published: 2020

Journal Articles

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-136574

Published: 2020

Journal Articles

Detailed Immunophenotypic Profiling of Peripheral Blood Immune Cells in Patients with Hematologic Malignancies after Sars-Cov-2 Infection

Forat Lutfi, MD, Jonathan Siglin, BS, Gabriela Sanchez-Petitto, MD, Ali Bukhari, MD, David Gottlieb, MD, Dong Won Kim, MD, Brandon Cooper, Michelle Fleyshman, MD, Diego De Miguel Perez, PhD, Michael Kleinberg, MD PhD, Rena G Lapidus, PhD, Aaron P. Rapoport, MD, Xiaoxuan Fan, PhD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-143160

Published: 2020

Journal Articles

Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, David Gottlieb, MBBS, MD FRACP, FRCPA, Travis Perera, MB ChB, FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Stephen R Larsen, MBBS PhDFRACP FRCPA, Richard Doocey, MB ChB, FRACP, FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Simon Durrant, MBBS FRCP FRCPath, Anne-Marie Watson, FRACP, FRCPA, MBBS, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Cameron Curley, MBBS, FRACP, FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-139057

Published: 2020

Journal Articles

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Stephen R Larsen, MBBS PhDFRACP FRCPA, Andrew Spencer, Travis Perera, MB ChB, FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Simon Durrant, MBBS FRCP FRCPath, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Anne-Marie Watson, FRACP, FRCPA, MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Richard Doocey, MB ChB, FRACP, FRCPA, Hugh J. Goodman, FRACP, Ian H. Kerridge, FRACP FRCPA MPhil BA, Christopher Arthur, Cameron Curley, MBBS, FRACP, FRCPA, Caroline Stewart, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, Jennifer Collins, Julian Cooney, FRACP,FRCPA,MBBS,, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139076

Published: 2020

Journal Articles

Donor-Derived T-Cells Specific for WT1 and PRAME in Combination with T-Cells Specific for Multiple Pathogens for Prevention of Relapse and Infection after Haemopoietic Stem Cell Transplant (HSCT) for Acute Myeloid Leukaemia (AML) or High-Risk Myelodysplasia (MDS) - (The INTACT Trial)

Wei Jiang, MBBS, M Clin MD FRACP, FRCPA, Emily Blyth, B. MDHons), FRACP, FRCPA, PhD, Peter J. Shaw, MA,FRACP, Leighton Edward Clancy, BSc, PhD, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, Abir Bhattacharyya, MBBS, FRACP, FRCPA, Elissa Atkins, RN, Selmir Avdic, PhD, Gaurav Sutrave, MBBS, FRACP, FRCPA, Janine Street, BSc MSc (Hons), David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 38.

https://doi.org/10.1182/blood-2020-143136

Published: 2020

Journal Articles

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Dong Won Kim, MD, Forat Lutfi, MD, Facundo Zafforoni, BS, Moaath Mustafa Ali, MD MPH, Ali Bukhari, MD, David Gottlieb, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Nancy M. Hardy, MD, Jean A. Yared, MD, Aaron P. Rapoport, MD, Jennie Y. Law, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141992

Published: 2020

Journal Articles

An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation

Kirsty M Sharplin, MBBS, David Ritchie, MB ChB, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Shyam Panicker, MBBS,MDMRCP,FRACP,FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Julian Cooney, FRACP,FRCPA,MBBS,, Richard Doocey, MB ChB, FRACP, FRCPA, Leanne Berkahn, MD, Sam Milliken, MBBS, FRACP, FRCPA, Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, FRCPath, Andrew Spencer, David J. Curtis, MBBS,PhD, Sushrut S. Patil, Stephen R Larsen, MBBS PhDFRACP FRCPA, Travis Perera, MB ChB, FRACP, FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Matthew Greenwood, MBBS, FRACP, FRCPA, Anne-Marie Watson, FRACP, FRCPA, MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Eric Wong, MDPhD FRACP, FRCPA, Steven Tran, BEng MBiomedE, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-138684

Published: 2020

Journal Articles

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Munoz, Alessandra Tedeschi, Andrew W. Roberts, John F. Seymour, Siminder Kaur Atwal, Yiling Yu, William Novotny, Eric Holmgren, Ziwen Tan, James D. Hilger, Jane Huang, Constantine S. Tam

Blood (2020) 136 (18): 2027–2037.

https://doi.org/10.1182/blood.2020006449

Published: 2020

Includes: Supplemental data

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

David Gottlieb, MBBS, MD FRACP, FRCPA, Wei Jiang, MBBS, BSc, BA, Selmir Avdic, PhD, Leighton Clancy, BSc PhD, Gaurav Sutrave, MBBS, Caroline M Bateman, PhDMBBS,FRACP,FRCPath,MRCP, Elissa Atkins, RN, Adrian Gabriel Selim, MBBS, Vicki Antonenas, BSc, David Collins, RN BSc (HONS) MN MapptMgt, Janine Street, BSc MSc (Hons), Renee Simms, BSc, Peter J. Shaw, MA,FRACP, David Ritchie, MD PhD, Emily Blyth, B. MDHons), FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 251.

https://doi.org/10.1182/blood-2019-125166

Published: 2019

Journal Articles

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

Glen A Kennedy, MBBS FRACP FRCPA, Siok-Keen Tey, MBBS,PhDFRACP,FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Ashish Misra, MBBS, FRACP, Elango Subramoniapillai, MBBS, FRACP, James Morton, MBBS, FRACP, FRCPA, Simon Durrant, FRCP,FRCPath,MBBS, Andrea S Hendon, MBBS, PhD FRACP, FRCPA, John Moore, MDFRACP,FRCPA, David Ritchie, MD PhD, David Gottlieb, MBBS, MD FRACP, FRCPA, Julian Cooney, FRACP,FRCPA,MBBS,, Luke Buizen, BSc (Hons), MSc, Sanjoy K Paul, PhD, Geoff R. Hill, MD

Blood (2019) 134 (Supplement_1): 368.

https://doi.org/10.1182/blood-2019-126285

Published: 2019

Journal Articles

An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era

Blood (2019) 134 (Supplement_1): 5719.

https://doi.org/10.1182/blood-2019-126547

Published: 2019

Journal Articles

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Blood (2019) 134 (11): 851–859.

https://doi.org/10.1182/blood.2019001160

Published: 2019

Includes: Supplemental data

Journal Articles

Co-Administration of 3 rd party Partially HLA Matched Cytomegalovirus Specific T Cells with Initial Antiviral Pharmacotherapy for Post-Transplant Viral Reactivation

Emily Blyth, B. MDHons), FRACP, FRCPA, PhD, Leighton Edward Clancy, PhD, Elissa Atkins, GIllian Huang, David Collins, David Bishop, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 2051.

https://doi.org/10.1182/blood-2018-99-117417

Published: 2018

Journal Articles

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

Constantine S. Tam, MBBS, MD FRACP, FRCPA, David Simpson, MBChB, Stephen Opat, FRACP, FRCPA, Won Seog Kim, MD, Ph. D., Michael Wang, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Patrick B Johnston, MD PhD, Javier Munoz, MD, Won-Sik Lee, MD, Paula Marlton, MBBS, David Gottlieb, MBBS, MD FRACP, FRCPA, Lai Wang, PhD, Jane Huang, MD, James Hilger, Ling Xue, PhD, Sunhee Ro, PhD, Judith Trotman, FRACP

Blood (2017) 130 (Supplement 1): 152.

https://doi.org/10.1182/blood.V130.Suppl_1.152.152

Published: 2017

NARROW

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

Detailed Immunophenotypic Profiling of Peripheral Blood Immune Cells in Patients with Hematologic Malignancies after Sars-Cov-2 Infection

Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Donor-Derived T-Cells Specific for WT1 and PRAME in Combination with T-Cells Specific for Multiple Pathogens for Prevention of Relapse and Infection after Haemopoietic Stem Cell Transplant (HSCT) for Acute Myeloid Leukaemia (AML) or High-Risk Myelodysplasia (MDS) - (The INTACT Trial)

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Co-Administration of 3 rd party Partially HLA Matched Cytomegalovirus Specific T Cells with Initial Antiviral Pharmacotherapy for Post-Transplant Viral Reactivation

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only